Source comparison
BPC-157 Support Joint Mobility Research: Type Comparison
Rodent tendon transection models Sprague-Dawley rats, C57BL/6 mice Histological collagen density, biomechanical tensile strength, inflammatory cytokine levels (IL-6, TNF-alpha) Controlled experimental conditions, reproducible dosing, mechanistic pathway identi
This comparison does not assign a generated winner or score.
- Rodent tendon transection models
- Sprague-Dawley rats, C57BL/6 mice
- Histological collagen density, biomechanical tensile strength, inflammatory cytokine levels (IL-6, TNF-alpha)
- Controlled experimental conditions, reproducible dosing, mechanistic pathway identification
- Multiple published studies; mechanism established but limited translatability to chronic human conditions
- In vitro fibroblast migration assays
- Human tenocyte cell lines
- FAK-paxillin activation, fibroblast migration velocity, VEGF gene expression
- Isolated mechanism clarity, dose-response characterisation possible
- Demonstrates plausible pathway but lacks systemic and load-bearing context
- Observational athlete cohorts
- Human athletes with Achilles or patellar tendinopathy
- Patient-reported pain scores, return-to-sport timelines, subjective improvement
- Real-world usage data, feasibility confirmation
- No randomisation or blinding; selection bias and placebo effects uncontrolled; published 2023 pilot (n=41) lacked objective mobility measures
- Controlled human RCTs
- None completed as of early 2026
- Would measure goniometric range-of-motion, functional performance tests (hop distance, stair speed), patient-reported outcome scores (DASH, VISA-A)
- Would provide causal evidence if properly blinded and powered
- Recruitment-phase trials exist (Stanford PRP combination study) but no published results yet
- Combination therapy trials (BPC-157 + PRP)
- Recruiting in 2026
- Ultrasound tendon thickness, ankle dorsiflexion ROM, VISA-A scores at 12 weeks
- Tests synergistic hypothesis; addresses real-world clinical application
- Trial ongoing; results expected late 2026 or early 2027